Solid Biosciences (NASDAQ:SLDB) had its price objective cut by stock analysts at Nomura from $52.00 to $37.00 in a report issued on Monday. The brokerage currently has a “buy” rating on the stock. Nomura’s target price would indicate a potential upside of 297.85% from the company’s current price.
Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. cut Solid Biosciences from a “neutral” rating to an “underweight” rating and set a $28.00 price target for the company. in a research note on Thursday. Chardan Capital began coverage on Solid Biosciences in a research note on Wednesday, February 21st. They issued a “buy” rating and a $40.00 price target for the company. Leerink Swann began coverage on Solid Biosciences in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $36.00 price target for the company. Goldman Sachs began coverage on Solid Biosciences in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $31.00 price target for the company. Finally, Instinet began coverage on Solid Biosciences in a research note on Tuesday, February 20th. They issued a “buy” rating and a $52.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $37.33.
Shares of Solid Biosciences stock traded down $0.27 during mid-day trading on Monday, hitting $9.30. The stock had a trading volume of 62,773 shares, compared to its average volume of 398,930. Solid Biosciences has a 12 month low of $8.95 and a 12 month high of $33.74.
COPYRIGHT VIOLATION WARNING: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3277812/nomura-cuts-solid-biosciences-sldb-price-target-to-37-00.html.
Solid Biosciences Company Profile
Solid Biosciences Inc, formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.